Drug Product Filled with Berkshire Sterile’s Low Loss Fill Process Receives FDA Greenlight Lee, MA, May 18, 2023 (GLOBE NEWSWIRE) -- RNAimmune, a biotech company focused on developing groundbreaking mRNA therapies, recently received FDA approval to begin Phase 1 clinical studies for an...

Exavir Therapeutics announces preclinical data demonstrating complete elimination of HIV from human cells with LNP-delivered Tat-targeted CRISPR-Cas9 Early candidate from XVIR-TAT series demonstrated genetic elimination of HIV and robust anti-retroviral activity with CRISPR-Cas9 based excision Exavir lipid nanoparticles (LNPs) with mRNA...

CRISPR Therapeutics Announces Exclusive License of Lipid Nanoparticle Technologies Developed at MIT BASEL, Switzerland and CAMBRIDGE, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...